William Blair Investment Management LLC decreased its position in Krystal Biotech, Inc. (NASDAQ:KRYS – Free Report) by 8.6% during the 3rd quarter, Holdings Channel.com reports. The firm owned 520,925 shares of the company’s stock after selling 49,228 shares during the period. William Blair Investment Management LLC’s holdings in Krystal Biotech were worth $173,239,000 as of its most recent filing with the Securities and Exchange Commission.
Several other institutional investors and hedge funds also recently made changes to their positions in the company. Allworth Financial LP boosted its stake in Krystal Biotech by 28.6% in the 3rd quarter. Allworth Financial LP now owns 603 shares of the company’s stock valued at $201,000 after purchasing an additional 134 shares during the period. Fifth Third Bancorp grew its holdings in Krystal Biotech by 1.4% in the 3rd quarter. Fifth Third Bancorp now owns 6,611 shares of the company’s stock valued at $2,199,000 after buying an additional 90 shares in the last quarter. New Mexico Educational Retirement Board bought a new position in Krystal Biotech during the 3rd quarter worth $1,829,000. Jacobi Capital Management LLC bought a new position in Krystal Biotech during the 3rd quarter worth $56,000. Finally, New York Life Investment Management LLC increased its position in Krystal Biotech by 10.4% during the 3rd quarter. New York Life Investment Management LLC now owns 3,497 shares of the company’s stock worth $1,163,000 after buying an additional 330 shares during the period. Institutional investors and hedge funds own 86.29% of the company’s stock.
Insiders Place Their Bets
In other Krystal Biotech news, insider Suma Krishnan sold 25,000 shares of the business’s stock in a transaction on Friday, September 4th. The shares were sold at an average price of $359.32, for a total transaction of $8,983,000.00. Following the sale, the insider owned 1,302,145 shares of the company’s stock, valued at approximately $467,886,741.40. The trade was a 1.88% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 13.10% of the stock is owned by corporate insiders.
Krystal Biotech Stock Performance
KRYS opened at $305.23 on Monday. The company has a market cap of $9.04 billion, a P/E ratio of 41.42 and a beta of 0.56. The company’s 50 day moving average is $326.76 and its 200-day moving average is $309.70. Krystal Biotech, Inc. has a 1-year low of $198.02 and a 1-year high of $382.54.
Krystal Biotech (NASDAQ:KRYS – Get Free Report) last released its quarterly earnings data on Monday, November 2nd. The company reported $2.05 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.79 by $0.26. The business had revenue of $127.34 million during the quarter, compared to analysts’ expectations of $125.77 million. Krystal Biotech had a net margin of 47.91% and a return on equity of 17.02%. On average, equities analysts forecast that Krystal Biotech, Inc. will post 7.74 EPS for the current year.
Analyst Upgrades and Downgrades
A number of equities research analysts have recently weighed in on the company. Chardan Capital raised Krystal Biotech to a “strong-buy” rating in a report on Monday, August 3rd. TD Cowen decreased their price target on shares of Krystal Biotech from $403.00 to $380.00 and set a “buy” rating on the stock in a research note on Tuesday, November 3rd. Weiss Ratings lowered shares of Krystal Biotech from a “buy (b)” rating to a “buy (b-)” rating in a research report on Wednesday, November 4th. Zacks Research lowered shares of Krystal Biotech from a “hold” rating to a “strong sell” rating in a research report on Friday, October 23rd. Finally, The Goldman Sachs Group began coverage on shares of Krystal Biotech in a research note on Thursday, September 24th. They issued a “buy” rating and a $441.00 price objective for the company. Two analysts have rated the stock with a Strong Buy rating, ten have assigned a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Krystal Biotech presently has a consensus rating of “Moderate Buy” and an average price target of $375.00.
View Our Latest Stock Analysis on KRYS
Krystal Biotech Company Profile
Krystal Biotech, Inc. is a biotechnology company that develops genetic medicines for people with serious diseases. Founded in 2016 and headquartered in Pittsburgh, Pennsylvania, the company focuses on treatments that deliver functional genes to patients’ cells. Its commercial product, Vyjuvek (beremagene geperpavec-svdt), is a topical gene therapy for wounds associated with dystrophic epidermolysis bullosa, a rare inherited skin disorder. The treatment is designed to help cells produce collagen VII, a protein that supports the skin’s structure.
Further Reading
- Five stocks we like better than Krystal Biotech
- Fossil Just Turned a Profit—Can Its Comeback Survive the Holidays?
- Beaming Up the Backlog: AeroVironment Lands $405M Laser Deal
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
Want to see what other hedge funds are holding KRYS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Krystal Biotech, Inc. (NASDAQ:KRYS – Free Report).
Receive News & Ratings for Krystal Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Krystal Biotech and related companies with MarketBeat.com's FREE daily email newsletter.
